

RECEIVED  
CENTRAL FAX CENTER

MAY 17 2004

**OFFICIAL**

<b>REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL</b> <small>Address to: Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</small>		Application Number 09/845,514
		Filing Date April 30, 2001
		First Named Inventor Aoki
		Group Art Unit 1645
		Examiner Name Ford, V.L.
		Attorney Docket No. D2929-CON

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

**1. Submission required under 37 CFR 1.114**

a.  Previously submitted

i.  Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on \_\_\_\_\_  
(Any unentered amendment(s) referred to above will be entered).

ii.  Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_

iii.  Other \_\_\_\_\_

b.  Enclosed

i.  Amendment/Reply

ii.  Affidavit(s)/Declaration(s)

iii.  Information Disclosure Statement (IDS)

iv.  Other \_\_\_\_\_

**2. Miscellaneous**

a.  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(b) required)

b.  Other \_\_\_\_\_

**3. Fees** The RCE fee under 37 CFR 1.17 (e) is required by 37 CFR 1.114 when the RCE is filed.

a.  The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 01-0885

i.  RCE fee required under 37 CFR 1.17(e)

ii.  Extension of time fee (37 CFR 1.136 and 1.17)

iii.  Other \_\_\_\_\_

b.  Check in the amount of \$ \_\_\_\_\_ enclosed


c.  Payment by credit card (Form PTO-2038 enclosed)

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print/Type)	Frank J. Uxa	Registration No. (Attorney/Agent)	25,612
Signature			
	Date	May 17, 2004	

**CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted to the U.S. Patent and Trademark Office on: May 17, 2004

Name (Print/Type)	Janet McGhee
Signature	
	Date
	May 17, 2004

Appl. No. 09/845,514  
Reply to Office Action of January 15, 2004

RECEIVED  
CENTRAL FAX CENTER  
MAY 17 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 09/845,514 Confirmation No.  
Applicant : Aoki et al.  
Filed : April 30, 2001  
Title : MULTIPLE BOTULINUM TOXINS FOR TREATING  
NEUROMUSCULAR DISORDERS AND CONDITIONS  
  
TC/A.U. : 1600/1645  
Examiner : Ford, V.L.  
  
Docket No. : D-2929 CON  
Customer No. : 33197

OFFICIAL  
3428

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

CERTIFICATE OF FACSIMILE TRANSMISSION  
I hereby certify that this correspondence is being  
transmitted via facsimile to Mail Stop RCE,  
Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450, to fax number 703-872-  
9306, on the date indicated below.

May 17 2004  
Saret M. McLean

AMENDMENT

Sir:

In response to the Final Office Action of January 15, 2004  
and the Advisory Action of April 16, 2004, please amend the  
above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims  
which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.